Analytical and pharmacological aspects of therapeutic drug monitoring of mtor inhibitors

Current Drug Metabolism

Volumn 12, Issue 3, 2011, Pages 253-267

  Pieri, Maria ^a   Miraglia, Nadia ^b   Polichetti, Giuliano ^a   Tarantino, Giovanni ^a   Acampora, Antonio ^a   Capone, Domenico ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Immunoassays; LC MS; LC UV; MTOR inhibitors; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ALFENTANIL; BROMOCRIPTINE; CLARITHROMYCIN; CYTOCHROME P450 3A; DANAZOL; DAPSONE; DEXTROMETHORPHAN; DILTIAZEM; DOXYCYCLINE; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; HYDROCORTISONE; ISONIAZID; KETOCONAZOLE; LIDOCAINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METOCLOPRAMIDE; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; NORFLOXACIN; ORAL CONTRACEPTIVE AGENT; RAPAMYCIN; VERAPAMIL; VORICONAZOLE;

ANEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; IMMUNOASSAY; IN VIVO STUDY; INFECTION; INTERMETHOD COMPARISON; KIDNEY DISEASE; NONHUMAN; PHARMACODYNAMICS; PROTEINURIA; ULTRAVIOLET RADIATION; WOUND HEALING;

ANIMALS; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79953672731     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795101868     Document Type: Article

References (146)

1. Morath, C.; Arns, W.; Schwenger, V.; Mehrabi, A.; Fonouni, H.; Schmidt, J.; Zeier, M. Sirolimus in renal transplantation. Nephrol. Dial. Transplant., 2007, 22 Suppl 8, viii61-viii65
2. Zuckermann, A.; Manito, N.; Epailly, E.; Fiane, A.; Bara, C.; Delgado, J. F.; Lehmkuhl, H.; Ross, H.; Eisen, H., Chapman, J.; Valantine, H. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J. Heart Lung Transplant., 2008, 27,141-149. (Pubitemid 351221042)
3. Aliabadi, A.Z.; Zuckermann, A. O.; Grimm, M. Immunosuppressive therapy in older cardiac transplant patients. Drugs Aging., 2007, 24, 913-932. (Pubitemid 350085753)
4. Harper, S. J.; Gelson, W.; Harper, I. G.; Alexander, G. J.; Gibbs, P. Switching to Sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation, 2010, Oct 28. [Epub ahead of print] doi: 10.1097/TP.0b013e3181fe131b.
5. Yoon, K. H. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option. Ann. N. Y. Acad. Sci., 2009, 1173, 752-756.
6. Fernandez, D.; Perl, A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov. Med., 2010, 9, 173-178.
7. Perl, A. Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome. Curr. Opin. Rheumatol., 2009, 21, 443-447.
8. Carlson, R. P.; Baeder, W. L.; Caccese, R. G.; Warner, L. M.; Sehgal, S. N. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann. N. Y. Acad. Sci., 1993, 685, 86-113. (Pubitemid 23238479)
9. Vignot, S.; Faivre, S.; Aguirre, D.; Raymond, E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol., 2005, 16, 525-537. (Pubitemid 40613318)
10. Bullock, K. E.; Petros, W. P.; Younis, I.; Uronis, H. E.; Morse, M. A.; Blobe, G. C.; Yousuf Zafar, S.; Gockerman, J. P.; Lager, J. J.; Truax, R.; Meadows, K. L.; Howard, L. A.; O'Neill, M. M.; Broadwater, G.; Hurwitz, H. I.; Bendell, J. C. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother. Pharmacol., 2010, Nov 16. [Epub ahead of print], DOI 10.1007/s00280-010- 1507-6.
11. Blasi, C. The autoimmune origin of atherosclerosis. Atherosclerosis., 2008, 201, 17-32
12. Ait-Oufella, H.; Taleb, S.; Mallat, Z.; Tedgui, A. Cytokine network and T cell immunity in atherosclerosis. Semin. Immunopathol., 2009, 31, 23-33.
13. Baetta, R.; Granata, A.; Canavesi, M.; Ferri, N.; Arnaboldi, L.; Bellosta, S.; Pfister, P.; Corsini, A. Everolimus inhibits monocyte/ macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J. Pharmacol. Exp. Ther., 2009, 328, 419-425.
14. Zimmerman, J. J.; Ferron, G. M.; Lim, H. K.; Parker, V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J. Clin. Pharmacol., 1999, 39, 1155-1161. (Pubitemid 30644018)
15. Mahalati, K.; Kahan, B. D. Clinical pharmacokinetics of sirolimus. Clin. Pharmacokinet., 2001, 40, 573-585. (Pubitemid 32758580)
16. Stenton, S. B.; Partovi, N.; Ensom, M. H. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin. Pharmacokinet., 2005, 44, 769-786. (Pubitemid 41126927)
17. Rangan, G. K.; Nguyen, T.; Mainra, R.; Succar, L.; Schwensen, K. G.; Burgess, J. S.; Ho, K. O. Therapeutic role of sirolimus in nontransplant kidney disease. Pharmacol. Ther., 2009, 123, 187-206.
18. Kovarik, J. M.; Noe, A.; Berthier, S.; McMahon, L., Langholff, W. K.; Marion, A. S.; Hoyer, P. F.; Ettenger, R.; Rordorf, C. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. J. Clin. Pharmacol., 2003, 43, 141-147. (Pubitemid 36125940)
19. Kovarik, J. M.; Hartmann, S.; Figueiredo, J.; Rordorf, C.; Golor, G.; Lison, A.; Budde, K.; Neumayer, H. H. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy, 2002, 22, 154-159. (Pubitemid 34112877)
20. Nashan, B. Review of the proliferation inhibitor everolimus. Expert Opin. Investig. Drugs, 2002, 11, 1845-1857.
21. Kirchner, G. I.; Meier-Wiedenbach, I.; Manns, M. P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet., 2004, 43, 83-95. (Pubitemid 38283132)
22. Pascual, J. Everolimus in clinical practice-renal transplantation. Nephrol. Dial. Transplant., 2006, 21(Suppl 3iii), 18-23.
23. Cummins, C. L.; Wu, C. Y.; Benet, L. Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther., 2002, 72: 474-489. (Pubitemid 36237718)
24. Demeule, M.; Labelle, M.; Régina, A.; Berthelet, F.; Béliveau, R. Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. Biochem. Biophys. Res. Commun., 2001, 281: 827-834. (Pubitemid 32917877)
25. Miller, D. S.; Fricker, G.; Drewe, J. p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J. Pharmacol. Exp. Ther., 1997, 282: 440-444. (Pubitemid 27425572)
26. Quezada, C.A.; Garrido, W.X.; González-Oyarzún, M.A.; Rauch, M. C.; Salas, M. R.; San Martín, R. E.; Claude, A. A.; Yañez, A. J.; Slebe, J.C.; Cárcamo, J. C. Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. Biol. Pharm. Bull., 2008, 31: 1911-1916.
27. Laplante, A.; Demeule, M.; Murphy, G. F.; Béliveau, R. Interaction of immunosuppressive agents rapamycin and its analogue SDZRAD with endothelial P-gp. Transplant. Proc., 2002, 34: 3393-3395. (Pubitemid 35463353)
28. Capone, D.; Palmiero, G.; Gentile, A.; Basile, V.; Federico, S.; Sabbatini, M.; Potenza, M.; Perfetti, A.; Pieri, M.; Tarantino, G. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. Curr. Drug Metab., 2007, 8, 379-381. (Pubitemid 46780065)
29. Capone, D.; Tarantino, G.; Gentile, A.; Sabbatini, M.; Polichetti, G.; Santangelo, M.; Nappi, R.; Ciotola, A.; D'Alessandro, V.; Renda, A., Basile, V.; Federico, S. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J. Clin. Pharm. Ther., 2010, 35, 121-124.
30. Capone, D.; Tarantino, G.; Polichetti, G.; Kadilli, I., Sabbatini, M., Basile, V., Carrano, R., Nappi, R., Federico, S. Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients. J. Clin. Pharmacol., 2010,50, 576-80.
31. Federico, S.; Carrano, R., Capone, D., Gentile, A., Palmiero, G., Basile, V. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin. Pharmacokinet., 2006, 45, 169-175. (Pubitemid 43290829)
32. Gurley, B. J.; Swain, A.; Williams, D. K.; Barone, G.; Battu, S. K. Gauging the clinical significance of P-glycoprotein-mediated herbdrug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol. Nutr. Food Res., 2008, 52, 772-779.
33. Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen, J. H.; Hsu, P. P.; Bagley, A. F.; Markhard A. L.; Sabatini, D. M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell., 2006, 22, 159-168.
34. Barilli, A.; Visigalli, R.; Sala, R.; Gazzola, G. C.; Parolari, A.; Tremoli, E.; Bonomini, S.; Simon, A.; Closs, E. I.; Dall'Asta, V.; Bussolati, O. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc. Res., 2008, 78, 563-571. (Pubitemid 351769758)
35. Ekberg, H.; Tedesco-Silva, H.; Demirbas, A.; Vítko, S.; Nashan, B.; Gürkan, A.; Margreiter, R.; Hugo, C.; Grinyó, J. M.; Frei, U.; Vanrenterghem, Y.; Daloze, P.; Halloran, P. F. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med., 2007, 357, 2562-2575. (Pubitemid 350294223)
36. Russ, G.; Segoloni, G.; Oberbauer, R.; Legendre, C.; Mota, A.; Eris, J.; Grinyó, J. M.; Friend, P.; Lawen, J.; Hartmann, A.; Schena, F. P.; Lelong, M.; Burke, J. T.; Neylan, J. F. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation, 2005, 80, 1204-1211. (Pubitemid 41746798)
37. Reitamo, S.; Spuls, P.; Sassolas, B.; Lahfa, M.; Claudy, A.; Griffiths, C. E. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br. J. Dermatol., 2001, 145, 438-445. (Pubitemid 32953701)
38. Letavernier, E.; Bruneval, P.; Mandet, C.; Duong Van Huyen, J. P; Péraldi, M. N.; Helal, I.; Noël, L. H.; Legendre, C. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin. J. Am. Soc. Nephrol., 2007, 2, 326-333.
39. Groth, C. G.; Bäckman, L.; Morales, J. M.; Calne, R.; Kreis, H.; Lang, P.; Touraine, J. L.; Claesson, K.; Campistol, J. M., Durand, D., Wramner, L.; Brattström, C., Charpentier, B. Sirolimus (rapamycin)- based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation, 1999, 67,1036-1042. (Pubitemid 29200856)
40. Kreis, H., Cisterne, J. M., Land, W., Wramner, L.; Squifflet, J. P.; Abramowicz, D., Campistol, J. M., Morales, J. M., Grinyo, J. M.; Mourad, G.; Berthoux, F. C., Brattström, C.; Lebranchu, Y.; Vialtel, P. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation, 2000, 69, 1252-1260. (Pubitemid 30238708)
41. Sabbatini, M., Sansone, G.; Uccello, F., De Nicola, L., Nappi, F., Andreucci, V. E. Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. Transplantation, 2000, 69, 1946-1990.
42. Marshall, E.K.J.; Dearborne, E.H. The relation of the plasma concentration of quinacrine to its antimalarian activity. J. Pharmacol. Exp. Ther. 1946, 88, 142-153.
43. Shaw, L.M.; Holt, D.W.; Keown, P.; Venkataramanan, R.; Yatscoff, R.W. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin. Ther. 1999, 21, 1632-1652. (Pubitemid 29523360)
44. Hallworth, M. In: Clarke's analysis of drugs and poisons. Moffat, A.C., Osselton, M.D., Widdop B., Eds.; Pharmaceutical Press: London, 2004; pp. 148-160.
45. Kahan, B.D.; Napoli, K.L.; Kelly, P.A.; Podbielski, J.; Urbauer, D.L.; Katz, S.H.; van Buren, C.T. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin. Transplant. 2000, 14, 97-109. (Pubitemid 30171208)
46. Holt, D.W.; Denny, K.; Lee, T.D.; Johnston, A. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant. Proc. 2003, 35 (Suppl. 3A), 157S-161S. (Pubitemid 36547938)
47. Kuypers, D.R.J. Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transplant. Int., 2005, 18, 140-150. (Pubitemid 41743303)
48. Brattström, C.; Säwe, J.; Tydén, G.; Herlenius, G.; Claesson, K.; Zimmerman, J.; Groth, C.G. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther. Drug Monit., 1997, 19, 397-406. (Pubitemid 28074035)
49. Chen, K.; Khayam-Bashi, H. Comparative analysis of antiepileptic drugs by gas chromatography using capillary or packed columns and by fluorescence polarization immunoassay. J. Anal. Toxicol., 1991, 15, 82-85.
50. Fryer, J.; Yatscoff, R.W.; Pascoe, E.A.; Thliveris, J. Transplant., 1993, 55, 340-342.
51. Yakimets, W.J.; Lakey, J.R.; Yatscoff, R.W.; Katyal, D.; Ao, Z.; Finegood, D.T.; Rajotte, R.V.; Kneteman, N.M. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation, 1993, 56, 1293-1298. (Pubitemid 24018772)
52. Kahan, B.D.; Podbielski, J.; Napoli, K.L.; Katz, S.M.; Meier- Kriesche, H.U.; Van Buren, C.T. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation, 1998, 66, 1040-1046. (Pubitemid 28513384)
53. Brattström, C.; Wilczek, H.; Tydèn, G.; Bottiger, Y.; Sawe, J.; Groth, C.G. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplantation, 1998, 65, 1272-1274. (Pubitemid 28224351)
54. Yatscoff, R.W.; Boeckx, R.; Holt, D.W.; Kahan, B.D.; LeGatt, D.F.; Sehgal, S.; Soldin, S.J.; Napoli, K.; Stiller, C. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther. Drug Monit., 1995, 17, 676-680.
55. Holt, D.W. Guidelines on Monitoring Rapamune (sirolimus). 2001, Wyeth Laboratories, Maidenhead, UK: 1.
56. Zimmerman, J.J.; Harper, D.; Getsy, J.; Jusko, W.J. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J. Clin. Pharmacol., 2003, 43, 1168-1176. (Pubitemid 37174449)
57. Kahan, B.D.; Camardo, J.S. Rapamycin: clinical results and future opportunities. Transplantation, 2001, 72, 1181-1193. (Pubitemid 33026593)
58. Meier-Kriesche, H.U.; Kaplan, B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin. Ther., 2001, 47, 1316-1319.
59. Sedrani, R.; Cottens, S.; Kallen, J.; Schuler, W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant. Proc., 1998, 30, 2192-2194. (Pubitemid 28399473)
60. Kovarik, J.M.; Sabia, H.D.; Figueiredo, J.; Zimmerman, H.; Reynolds, C.; Dilzer, S.C.; Lasseter, K.; Rordorf, C. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin. Pharmacol. Ther., 2001, 70, 425-430. (Pubitemid 33135321)
61. Kovaric, J.M.; Hsu, C.H.; McMahon, L.; Berthier, S.; Rordorf, C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin. Pharmacol. Ther., 2001, 70, 247-254. (Pubitemid 32868488)
62. Kovarik, J.M.; Eisen, H.; Dorent, R.; Mancini, D.; Vigano, M.; Roully, M.; Hsu, C.H.; Rordorf, C. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range and influence on cyclosporine exposure. J. Heart Lung Tranplant., 2003, 22, 1117-1125. (Pubitemid 37206567)
63. Kahan, B.D.; Kaplan, B.; Lorber, M.I.; Winkler, M.; Cambon, N.; Boger, R.S. RAD in de novo renal transplantation: comparison of three dises on the incidence and severity of acute rejection. Transpalnatation, 2001, 71, 1400-1406. (Pubitemid 32507112)
64. Kovarik, J.M.; Tedesco, H.; Pascual, J.; Civati, G.; Bizot, M.N.; Geissler, J.; Schmidli, H. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Thedr. Drug Monit., 2004, 26, 499-505. (Pubitemid 39314317)
65. Starling, R. C.; Hare, J.M.; Hauptman, P.; McCurry, K.R.; Mayer, H.W.; Kovarik, J.M.; Schmidli, H. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am. J. Transplant., 2004, 4, 2126-2131. (Pubitemid 39611643)
66. Jones, K; Saadat-Lajevardi, S; Lee, T; Horwatt, R.; Hicks, D.; Johnston, A.; Holt, D.W. An immunoassay for the measurement of sirolimus. Clin. Ther., 2000, 22(Suppl. B), B49-B61. (Pubitemid 30306045)
67. Morris, R. G.; Salm, P.; Taylor, P. J.; Wicks, F. A.; Theodossi, A. Comparison of the reintroduced MEIA® assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients. Ther. Drug Monit., 2006, 28(Suppl. B), 164-168. (Pubitemid 44314943)
68. US FDA, Food and Drug Administration: Center for Drug Evaluation and Research, 2001. Guidance for Industry: Bioanalytical Method Validation. Available on line: http://www.fda.gov/downloads/ Drugs/ GuidanceComplianceRegulatoryInformation/Guidance s/UCM070107.pdf (last assessed 02/08/2011).
69. Salm, P.; Taylor, P. J.; Pillans, P.I. The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients. Clin. Ther., 2000, 22, B71-B85. (Pubitemid 30306047)
70. Salm, P.; Taylor, P.J.; Pillans, P.I. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood. Clin. Chem., 1999, 45, 2278-2280.
71. Johnson, R. N.; Sargon, R.; Woollard, G.; Davidson, J. An evaluation of the Abbott IMx sirolimus assay in relation to a highperformance liquid chromatography-ultraviolet method. Ann. Clin. Biochem., 2005, 42, 394-397. (Pubitemid 41354402)
72. Pini, L. A.; Gallesi, D.; Brovia, D.; Bertolini, A.; Pinetti, D.; Ruggieri, V.; Pisa, S.; Poopi, B.; Castellana, C. N. Switching from HPLC/UV to MEIA for whole blood sirolimus quantitation: comparison of methods.
73. Pieri, M.; Capone, D.; Gentile, A.; Miraglia, N.; Leo, E.; Federico, S.; Basile, V.; Acampora, A. Immunoassay determination of rapamycin: reliability of the method with respect to liquid chromatography mass spectrometric quantification. Clin. Transplant., 2007, 21: 633-637. (Pubitemid 47399428)
74. Wilson, D.; Johnston, F.; Holt, D.; Moreton, M.; Engelmayer, J.; Gaulier, J.-M.; Luthe, H.; Marquet, P.; Moscato, D.; Oellerich, M.; Mosso, R.; Streit, F.; Brunet, M.; Fillee, C.; Schmid, R.; Wallemacq, P.; Barnes, G. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus. Clin. Biochem., 2006, 39, 378-386.
75. Bouzas, L.; Tutor, J.C. Determination of everolimus in whole blood using the Abbott IMx® sirolimus microparticle enzyme immunoassay. Clin. Biochem., 2007, 40, 132-136. (Pubitemid 46014154)
76. Pieri, M.; Miraglia, N.; Gentile, A.; Polichetti, G.; Castiglia, L.; Federico, S.; Sabbatini, M.; Basile, V.; Tarantino, G.; Acampora, A.; Capone, D. Quantification of sirolimus and everolimus by immunoassay techniques: tests specificity and cross-reactivity evaluation. Inter. J. Immunopathol. Pharmacol., 2008, 21, 585-594.
77. Bouzas, L.; Hermida, J.; Tutor, J.C. Determination of blood sirolimus concentrations in liver and kidney transplant recipients using the Innofluor® fluorescence polarization immunoassay: comparison with the microparticle enzyme immunoassay and highperformance liquid chromatography- ultraviolet method. Upsala J. Med. Sci., 2009, 114, 55-61.
78. Holt, D. W.; Lee, T.; Jones, K.; Johnston, A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin. Chem., 2000, 46, 1179-1183. (Pubitemid 30643322)
79. Westley, I. S.; Morris, R. G.; Taylor, P. T.; Salm, P.; James, M. J. CEDIA® sirolimus assay compared with HPLC-MS/MS and HPLC-UV in transplant recipient specimens. Ther. Drug Monit., 2005, 27, 309-314. (Pubitemid 40770988)
80. Henderson, D. R.; Friedman, S.; Harris, J. D.; Manning, W.B.; Zoccoli, M.A. CEDIATM, a new homogeneous immunoassay system. Clin. Chem., 1986, 32, 1637-1641. (Pubitemid 17020560)
81. Dandliker, W. B.; Kelly, R. J.; Danliker, J.; Farquahar, J.; Levin, J. Fluorescence polarization immunoassay. Theory and experimental method. Immunochem., 1973, 10, 219-227.
82. Boyd, J.; Arabshahi, L.; Roberts, M.; Marbach, P. A new FPIA immunoassay for the quantitative determination of everolimus in whole blood. Ther. Drug Monit., 2005, 27, 213-214.
83. Strom, T.; Boyd, J.; Arabshahi, L.; Marbach, P.; Christians, U. Cross-reactivity of the major everolimus hydroxy metabolites with the Innofluor® Certican® immunoassay for clinical TDM of everolimus. Ther. Drug Monit., 2005, 27, 243-.
84. Salm, P.; Warnholtz, C.; Boyd, J.; Arabshahi, L.; Marbach, P.; Taylor, P. Evaluation of a fluorescent polaritazion immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin. Biochem., 2006, 39, 732-738. (Pubitemid 44036785)
85. Baldelli, S.; Crippa, A.; Gabrieli, R.; Fiocchi, R.; Perico, N.; Merlini, S.; Ottomano, C.; Cattaneo, D. Comparison of the Innofluor® certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. Clin. Biochem., 2006, 39, 1152-1159. (Pubitemid 44848323)
86. Moes, D. J.; Press, R. R.; de Fijter, J. W.; Guchelaar, H. J.; den Hartigh, J. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. Ther. Drug Monit., 2010, 32: 413-419.
87. Crowe, A.; Bruelisauer, A.; Duerr, L.; Guntz, P.; Lemaire, M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab. Dispos., 1999, 27, 627-632. (Pubitemid 29214476)
88. Napoli, K.; Kahan, B. D. High performance liquid chromatography of rapamycin. Clin. Chem., 1991, 37, 294-295.
89. Yatscoff, R. W.; Faraci, C.; Bolingbroke, P. Measurement of rapamycin in whole blood using reverse-phase high performance liquid chromatography. Ther. Drug Monit., 1992, 14, 138-141.
90. Napoli, K.; Kahan, B. D. Sample clean-up and high performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J. Chromatogr. B, 1994, 654, 111-120. (Pubitemid 24103266)
91. Maleki, S.; Graves, S.; Becker, S.; Horwatt, R.; Hicks, D.; Stroshane, R. M.; Kincaid, H. Therapeutic drug minitoring of sirolimus in human whole-bllod samples by high performance liquid chromatography. Clin. Ther., 2000, 22(Suppl. B), B25-B37. (Pubitemid 30306043)
92. Holt, D. W.; Lee, T.; Johnston, A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin. Ther., 2000, 22(Suppl. B), B38-B48 (Pubitemid 30306044)
93. French, D. C.; Saltzgueber, M.; Hicks, D. R.; Cowper, A. L.; Holt, D. W. HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin. Chem., 2001, 47, 1316-1319. (Pubitemid 32579126)
94. Cattaneo, D.; Perico, N.; Gaspari, F. Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B, 2002, 774, 187-194. (Pubitemid 34655490)
95. Connor, E.; Sakamoto, M.; Fujikawa, K.; Law, T.; Rifai, N. Measurement of whole blood sirolimus by an HPLC assay using solidphase extraction and UV detection. Ther. Drug Monit., 2002, 24, 751-756. (Pubitemid 35379530)
96. Di Marco, G. S.; Camargo de Andrade, M. C.; Rosso Felipe, C.; Alfieri, F.; Gooding, A.; Tedesco Silva, H. J.; de Abreu Pestana, J. O.; Casarini, D. E. Determination of sirolimus blood concentration using high-performance liquid chromatography with ultraviolet detection. Ther. Drug Monit., 2003, 25, 558-564. (Pubitemid 37238889)
97. Fryer, J.; Yatscoff, R. W.; Pascoe, E. A.; Thliveris, J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heteropropic heart transplant model. Transplantation, 1993, 55, 340-345. (Pubitemid 23065466)
98. Napoli, K. L.; Kahan, B. D. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin. Chem., 1996, 42, 1943-1948. (Pubitemid 26415343)
99. Cordonnier, J.; Schaep, J. In: Clarke's analysis of drugs and poisons. Moffat, A.C., Osselton, M.D., Widdop B., Eds.; Pharmaceutical Press: London, 2004; pp. 313-327.
100. Baldelli, S.; Murgia, S.; Merlini, S.; Zenoni, S.; Perico, N.; Remuzzi, G.; Cattaneo, D. High-performnce liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. J. Chrom. B, 2005, 816, 99-105. (Pubitemid 40143495)
101. Boudennaia, T. Y.; Napoli, K. L. Validation of a practical liquid chromatography with ultraviolet detection method for quantification of whole-blood everolimus in a clinical TDm laboratory. Ther. Drug Monit., 2005, 27, 171-177. (Pubitemid 40463645)
102. Khoschsorur, G. Simultaneous measurement of sirolimus and everolimus in whole blood by HPLC with ultraviolet detection. Clin. Chem., 2005, 51, 1721-1724. (Pubitemid 41233112)
103. Sallustio, B. C.; Noll, B. D.; Morris, R. G. Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLC-UV and immunoassay methods. Clin. Biochem., 2010, doi: 10.1016/j. biochem.2010.10.005.
104. Khoschsorur, G. Simultaneous measurement of sirolimus and everolimus in whole blood by HPLC with ultraviolet detection. Clin. Chem., 2005, 51, 1721-1724. (Pubitemid 41233112)
105. Gelpi, E., Advances in Mass Spectrometry, 15th ed: Wiley & Sons:New York, 2001.
106. Streit, F.; Christians, U.; Schiebel H.-M.; Napoli, K. L.; EDrnst, L.; Linck, A.; Kahan, B. D.; Sewing, K.-F. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin. Chem., 1996, 42, 1417-1425. (Pubitemid 26300239)
107. Taylor, P. J.; Johnson, A. G. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatographyelectrospray tandem mass spectrometry. J. Chromatogr. B iomed Sci. Appl., 1998, 718, 251-257. (Pubitemid 28499999)
108. Taylor, P. J.; Salm, P.; Lynch, S. V.; Pillans, P. I. Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit., 2000, 608-612.
109. Holt, D. W.; Lee, T.; Jones, K.; Johnston, A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin. Chem., 2000, 46, 1179-1183. (Pubitemid 30643322)
110. Volosov, A.; Napoli, K. L.; Soldin, S. J. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. Clin. Biochem., 2001, 34, 285-290. (Pubitemid 32607570)
111. Vogeser, M.; Fleischer, C.; Meiser, B.; Groetzner, J.; Spöhrer, U.; Seidel, D. Quantification of sirolimus by liquid chromatographytandem mass spectrometry using on-line solid-phase extraction. Clin. Chem. Lab. Med., 2002, 40, 40-45. (Pubitemid 34196447)
112. Streit, F.; Armstrong, V. W.; Oellerich, M. Rapid liquid chromatography- tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporin. Clin. Chem., 2002, 48, 955-958. (Pubitemid 34587603)
113. Wallemacq, P. E.; Vanbinst, R.; Asta, S.; Cooper, D. P. Highthroughput liquid chromatography-tandem mass spectrometric analysis of sirolimus in whole blood. Clin. Chem. Lab. Med., 2003, 41, 921-925. (Pubitemid 37010186)
114. Koal, T.; Deters, M.; Casetta, B.; Kaever, V. Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry.
115. Ceglarek, U.; Lembcke, J.; Fiedler, G. M.; Werner, M.; Witzigmann, H.; Hauss, J. P.; Thiery, J. Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry. Clin. Chim. Acta, 2004, 346, 181-190. (Pubitemid 38901049)
116. Wang, S.; Miller, A. A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. Clin. Chem. Lab. Med., 2008, 46, 1631-1634.
117. Koster, R. E.; Dijkers, E. C. F.; Uges, D. R. A. Robust. hightroughput LC-MS/Ms method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus and sirolimus in whole blood. Ther. Drug Monit., 2009, 31, 116-125.
118. Kirchner, G.I.; Vidal, C.; Jacobsen, W.; Franzke, A.; Hallensleben, K.; Christians, U.; Sewing, K.-F. Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography- electrospray mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 1999, 721, 285-294. (Pubitemid 29142351)
119. Christians, U.; Jacobsen, W.; Serkova, N.; Benet, L. Z.; Vidal, C.; Sewing, K.-F.; Manns, M. P.; Kirchner, G. I. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography- mass spectrometry with on-line extraction: immunosuppressants. J. Chromatogr. B, 2000, 748, 41-53.
120. Kirchner, G.I.; Jacobsen, W.; Deters, M.; Christians, U.; Nashan, B.; Winkler, M.; Vidal, C.; Kaever, V.; Sewing, K.-F.; Manns, M. P. Fast quantification method for sirolimus and its major metabolites. Transplant. Proc., 2001, 33, 1091-1092. (Pubitemid 32237761)
121. Deters, M.; Kirchner, G.; Resch, K.; Kaever, V. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry. Clin. Chem. Lab. Med., 2002, 40, 285-292. (Pubitemid 34428858)
122. Hatsis, P.; Volmer, D. A. Evaluation of a cyano stationary phase for the determination of tacrolimus, sirolimus and cyclosporin A in whole blood by high-performance liquid-chromatography-tandem mass spectrometry. J. Chromatogr. B, 2004, 809, 287-294. (Pubitemid 39094707)
123. Pieri, M.; Miraglia, N.; Castiglia, L.; Genovese, G.; Basilicata, P.; Simonelli, A.; Acampora, A. Determination of rapamycin: quantification of the sodiated species by an ion trap mass spectrometer as an alternative to the ammoniated complex analysis by triple quadrupole. Rapid Commun. Mass Spectrom., 2005, 19, 3042-3050. (Pubitemid 41540731)
124. Tang, L.; Kerbarle, P. Dependence of ion intensity in electrospray mass spectrometry on the concentration of the analytes in the electrosprayed solution. Anal. Chem., 1993, 65: 3654-3668.
125. Taylor, P. J. Matrix effects: the Achilles heel of quantitative highperformance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem., 2005, 38: 328-334. (Pubitemid 40342863)
126. O'Halloran, S.; Ilett, K. F. Evaluation of a deuterium-labeled internal standard for the measument of sirolimus by high-throughput HPLC electrospray ionization tandem mass spectrometry. Clin. Chem., 2008, 54: 1386-1389.
127. Segarra, I.; Brazelton, T. R.; Guterman, N.; Hausen, B.; Jacobsen, W.; Morris, R. E.; Benet, L. Z.; Christians, U. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2- hydroxyethyl)rapamycin. J. Chromatgr. B, 1998, 720, 179-187 (Pubitemid 29000945)
128. McMahon, L. M.; Luo, S.; Hayes, M.; Tse, F. L. S. Highthroughput analysis of everolimus (RAD001) and cyclosporine A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system. Rapid Commun. Mass Spectrom., 2000, 14, 1965-1971.
129. Brignol, N.; McMahon, L. M.; Luo, S.; Tse, F. L. S. Highthroughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD001) and cyclosporine A (CsA) in whole blood. Rapid Commun. Mass Spectrom., 2001, 15, 898-907. (Pubitemid 32587177)
130. Salm, P.; Taylor, P. J.; Lynch, S. V.; Pillans, P. I. Quantification and stability of everolimus (SDZ RAD) in human blood by highperformance liquid chromatography-electrospray tandem mass spectrometry. J. Chromatgr. B, 2002, 722, 283-290. (Pubitemid 34499575)
131. Zhu, B.; Ou-Yang, D.-S.; Chen, X.-P-; Huang, S.-L.; Tan, Z.-R.; He, N.; Zhou, H.-H. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin. Pharmacol. Ther., 2001, 70, 455-461. (Pubitemid 33135325)
132. Chang, G. W. M.; Kam, P. C. A. The physiological and pharmacological roles of cytochrome P450 isoenzymes Anaesthesia, 1999, 54, 42-50.
133. Rodrigues, A. D. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol., 1999, 57, 465-480. (Pubitemid 29073324)
134. Frye, R. F.; Matzke, G. R.; Adedoyin, A.; Porter, A.; Branch, R. A. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Ther., 1997, 62, 365-376. (Pubitemid 27475220)
135. Ozono, S.; Yamaguchi, A.; Mochizuki, H.; Kawakami, T.; Fujimoto, K., Otani, T.; Yoshida, K.; Ichinei, M.; Yamashita, T.; Hirao, Y. Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis., 2002, 5: 128-131. (Pubitemid 34777896)
136. Testa, R.; Caglieris, S.; Risso, D.; Arzani, L.; Campo, N.; Alvarez, S.; Giannini, E., Lantieri, P. B.; Celle, G. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. Am. J. Gastroenterol., 1997, 92:2268-73.
137. Scott, R. J.; Palmer, J.; Lewis, I. A.; Pleasance, S. Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun. Mass Spectrom., 1999, 13, 2305-2319.
138. Streetman, D. S.; Bleakley, J. F.; Kim, J. S.; Nafziger, A. N.; Leeder, J. S.; Gaedigk, A.; Gotschall, R.; Kearns, G. L.; Bertino, J. S. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xantine oxidase with the "Coopestown cocktail". Clin. Pharmacol. Ther., 2000, 68, 375-383.
139. Damkier, P.; Brøsen, K. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin. Pharmacol. Ther., 2000, 68, 199-209. (Pubitemid 30659175)
140. Palmer, J. L.; Scott, R. J.; Gibson, A.; Dickens, M.; Pleasance, S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br. J. Clin. Pharmacol., 2001, 52, 555-561.
141. Chiainuvati, S.; Nafziger, A. N.; Leeder, J. S., Gaedidigk, A.; Kearns, G. L.; Sellers, E.; Zhang, Y.; Kashuba, A. D.; Rowland, E.; Bertino, J.S. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther., 2003, 74, 437-447. (Pubitemid 37357722)
142. Yin, O. Q. P.; Lam, S. S. L.; Lo, C. M. Y.; Chow, M. S. S. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry:application to cytochrome P450 phenotyping studies. Rapid Commun. Mass Spectrom., 2004, 18, 2921-2933. (Pubitemid 39576836)
143. Paolini, M.; Biagi, G. L.; Bauer, C.; Cantelli-Forti, G. Cocktail strategy: complications and limitations. J. Clin. Pharmacol., 1993, 33, 1011-1012.
144. Begas, E.; Kouvaras, E.; Tsakalof, A.; Papakosta, S.; Asprodini, E. K. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xantine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed. Chromatogr., 2007, 21, 190-200.
145. Carrillo, J. A.; Ramos, S. I.; Agundez, J. A. G.; Martinez, C.; Benitez, J. Analysis of midazolam and metabolites in plasma by highperformance liquid chromatography: probe of CYP3A. Ther. Drug Monit., 1998, 20, 319-324. (Pubitemid 28248853)
146. Zhu, B.; Ou-Yang, D. S. ; Cheng, Z. N. ; Huang, S. L. ; Zhou, H. H. Single plasma sampling to predict oral clearance of the CYP3A probe midazolam. Acta Pharmacol. Sin., 2001, 22, 634-638. (Pubitemid 32656493)